Image 1 of 4
Image 2 of 4
Image 3 of 4
Image 4 of 4
Packaging & supply options
Your format, your way.
The same research peptide, with a choice of accessories and supply formats. Here’s what each option includes.
BAC water
Vial kit
Lyophilised peptide vial with separately packaged, complimentary BAC water.
BAC water + syringes
Syringe kit
Lyophilised peptide vial, BAC water and syringes.
BAC water + pen
Injection pen kit
Lyophilised peptide vial, BAC water and an injection pen.
Pen + pen needles
Reconstituted pen
VIETNAM ONLYPeptide solution supplied in a pen at the stated concentration, with pen needles.
For laboratory research only. Not for human or veterinary use.
Everform Pharma · Research profile
Tesamorelin.
Exploring growth hormone signalling.
A closer look at GHRH signalling, visceral adipose tissue and liver-fat research — with the clinical evidence in context.
What is Tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), the signalling peptide that stimulates growth hormone release from the pituitary. Its research profile centres on visceral adipose tissue, growth hormone physiology and liver fat. [1]
Visceral fat surrounds internal organs and differs from subcutaneous fat beneath the skin. A change in one compartment does not necessarily mean the same change in body weight, waist appearance or total body fat.
The strongest clinical evidence discussed here comes from adults with HIV-associated abdominal fat accumulation. Additional trials have examined selected adults with obesity and reduced growth hormone secretion. These populations should not be treated as interchangeable with healthy athletes or the general population. [1] [4]
How it works
Tesamorelin acts through GHRH receptors on pituitary somatotroph cells, stimulating endogenous growth hormone secretion and downstream IGF-1 production. It is a GHRH analogue rather than growth hormone itself. [5]
Growth hormone signalling influences lipid metabolism and body composition. Tesamorelin trials have therefore measured visceral fat by imaging alongside IGF-1, glucose and other metabolic markers. Changes in these measurements are distinct outcomes, not a single measure of “metabolic improvement”. [1] [2]
GHRH → GH → IGF-1
Investigating pituitary signalling and its downstream endocrine response.
MEASURING FAT DISTRIBUTION
Distinguishing visceral adipose tissue from subcutaneous fat and overall body weight.
Main research areas
| Research area | What the evidence addresses |
|---|---|
| Visceral adipose tissue | Randomised human trials in HIV-associated abdominal adiposity assessed changes in internal abdominal fat using imaging. Findings do not establish general weight-loss benefits. [1] [2] |
| Liver fat | Human studies in people with HIV examined hepatic fat, including a trial enrolling participants with non-alcoholic fatty liver disease (NAFLD). [2] [3] |
| GH and IGF-1 signalling | Clinical work measured the endocrine response to a GHRH analogue. Higher IGF-1 is a biological effect and a safety consideration, not automatically a benefit. [5] |
| Selected obesity populations | A separate randomised trial studied adults with obesity and relative reductions in GH secretion. Its findings do not cover every person with obesity. [4] |
These are human clinical studies of defined investigational or medicinal formulations. They do not validate the identity, quality or clinical performance of an Everform research vial.
What published findings show
Abdominal fat in HIV: Falutz and colleagues reported that visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% with placebo over 26 weeks. This was an imaging outcome in adults with HIV-associated abdominal fat accumulation, not a percentage reduction in total body weight. [1]
Visceral and liver fat: A 2014 randomised trial involving 50 adults with HIV and abdominal fat accumulation found reductions in both visceral adipose tissue and liver fat relative to placebo over six months. It did not establish the same results in otherwise healthy people. [2]
HIV-associated fatty liver: In a 2019 trial, the between-group effect on hepatic fat fraction was approximately 4.1 percentage points lower with tesamorelin over 12 months. This corresponded to a 37% relative reduction from baseline. These figures describe liver fat, not body-fat percentage; longer-term effects on liver histology require further research. [3]
Obesity with reduced GH secretion: A separate study reported a selective reduction in visceral fat without a significant change in subcutaneous fat. This supports studying fat compartments separately and does not establish a universal slimming effect. [4]
The clinical evidence is population-specific. It does not demonstrate guaranteed fat loss, athletic performance gains, longer life or cardiovascular protection. The medicinal product’s prescribing information also identifies elevated IGF-1, fluid retention and glucose intolerance as safety considerations. [5]
The Everform product, at a glance
ProductTesamorelin
Labelled vial amount10 mg
Vial formatLyophilised peptide powder
Supply optionsCheck the current product selector
Everform Pharma is based in Da Nang, Vietnam. The labelled 10 mg describes vial content, not a recommended dose. Complimentary BAC water is included with every order.
Explore Your format, your way →
The full REF on the product should match the relevant documentation. The security sticker repeats the product identifier and should match the vial or pen; it is not a separate new ID. Check the actual product label for storage and expiry information.
Identity, chromatographic purity and measured peptide content are different analytical results. A published trial does not establish the quality of a separate research product, and a purity percentage alone does not establish the amount of peptide in a vial.
Common questions
Is Tesamorelin the same as growth hormone?
No. It is a GHRH analogue that stimulates endogenous GH secretion. Growth hormone is the downstream hormone. [5]
Is visceral fat the same as the fat beneath the skin?
No. Visceral fat is located around internal organs; subcutaneous fat lies beneath the skin. Clinical studies measure these compartments separately. [1] [4]
Do the trials prove general weight-loss or bodybuilding benefits?
No. The cited trials concern defined populations and endpoints. A reduction in visceral fat is not equivalent to proven weight-loss management or improved athletic performance. The US medicinal product is not indicated for weight-loss management. [5]
Does the liver-fat evidence apply to everyone with fatty liver?
No. The cited 2019 study enrolled people with HIV and NAFLD. Results should not automatically be extended to other populations or treated as proof of long-term liver benefit. [3]
Is the Everform vial equivalent to the clinical-trial product?
This article does not establish equivalence. Clinical results relate to the specific formulations, quality controls and study conditions described in the original research.
Does 10 mg describe a recommended dose?
No. It describes labelled vial content, not an administration amount, schedule or protocol.
References
Everform Pharma · Da Nang, Vietnam
Educational product information.
For laboratory research only.
Not for human or veterinary use.
